Advanced Filters
noise

progressive-supranuclear-palsy Clinical Trials

A listing of progressive-supranuclear-palsy medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Found 35 clinical trials
K Kara McHaney

AMX0035 and Progressive Supranuclear Palsy

ORION Trial is a trial to evaluate the efficacy and safety of AMX0035 in participants with Progressive Supranuclear Palsy (PSP), consisting of a randomized double blind placebo controlled phase, followed by an optional open-label extension phase.

40 - 80 years of age Both Phase 3
B Benzi Kluger, MD

Community Outreach for Palliative Engagement -- Parkinson Disease

The purpose of this study is to learn more about the effectiveness of palliative care training for community physicians and telemedicine support services for patients and carepartners with Parkinson's disease and Lewy Body Dementia (LBD) or related conditions and their care partners. Palliative care is a treatment approach focused on …

40 - 100 years of age Both Phase N/A
R Research Coordinator

Trial of Parkinson's and Zoledronic Acid

This home-based study is a randomized (1:1) placebo-controlled trial of a single infusion of zoledronic acid-5 mg (ZA) for the prevention of fractures in men and women aged 60 years and older with Parkinson's disease and parkinsonism with at least 2 years of follow-up. A total of 3500 participants will …

60 - 100 years of age Both Phase 4
E Erik Stomrud, MD, PhD

The Swedish BioFINDER 2 Study

The Swedish BioFINDER 2 study is a new study that will launch in 2017 and extends the previous cohorts of BioFINDER 1 study (www.biofinder.se). BioFINDER 1 is used e.g. to characterize the role of beta-amyloid pathology in early diagnosis of Alzheimer's disease (AD) using amyloid-PET (18F-Flutemetamol) and Aβ analysis in …

20 - 100 years of age Both Phase N/A
G Graham Harker

Transcranial Magnetic Stimulation in Progressive Supranuclear Palsy

The objective of this proposal is to investigate the effect of non-invasive repetitive cerebellar transcranial magnetic stimulation (rTMS) on motor control in progressive supranuclear (PSP). The central hypothesis is that augmenting cerebellar inhibition via cerebellar rTMS will decrease postural instability in patients with PSP. We will use functional near infrared …

40 - 85 years of age Both Phase N/A

GV1001 Subcutaneous(SC) for the Treatment of Progressive Supranuclear Palsy (PSP)

The study will be conducted by the Sponsor to evaluate the efficacy and safety of GV1001 (0.56 mg and 1.12 mg) administered subcutaneously as a treatment for Progressive Supranuclear Palsy, (PSP). In 75 patients diagnosed with PSPR Richardson(PSP-RS) or PSP-Parkinsonism (PSP-P) at five hospitals in Korea, subcutaneous administration of GV1001 …

41 - 85 years of age Both Phase 2
S Sarah M Boland, CCRP

A Molecular Anatomic Imaging Analysis of Tau in Progressive Supranuclear Palsy

This study is designed to learn more about overall tau burden in the brain of patients with Progressive Supranuclear Palsy (PSP).

35 - 100 years of age Both Phase N/A

Administration of GV1001 for the Treatment of Progressive Supranuclear Palsy Who Completed Study GV1001-PSP-CL2-011

The study will be conducted by the Sponsor to evaluate Twelve-months Long-Term Safety and Efficacy of GV1001 (1.12 mg) administered subcutaneously as a treatment for Progressive Supranuclear Palsy(PSP). In 75 patients diagnosed with PSP Richardson(PSP-RS) or PSP-Parkinsonism (PSP-P) who Completed Study GV1001-PSP-CL2-011.

41 - 85 years of age Both Phase 2
S Sarah Margott

A Study to Assess the Efficacy, Safety, and Pharmacokinetics of FNP-223 to Slow Progression of Progressive Supranuclear Palsy (PSP)

PROSPER trial is a trial to assess the efficacy of FNP-223 in slowing disease progression in participants with PSP as measured by the PSP Rating Scale (PSPRS) over 52 weeks and to assess the safety and tolerability of FNP-223 for 52 weeks in participants with PSP.

50 - 80 years of age Both Phase 2

Evaluation of [18F]APN-1607 as a PET Biomarker

The overall goal of this protocol is to evaluate [18F]APN-1607 as a PET radiotracer for measuring longitudinal change in tau pathology in participants with PSP.

50 - 80 years of age Both Phase 1

Rewrite in simple language using AI